meropenem

Meropenem (SM 7338) is a broad-spectrum carbapenem antibiotic administered intravenously for severe bacterial infections caused by sensitive agents. It commonly causes mild, transient aminotransferase elevations and can rarely lead to clinically apparent cholestatic liver injury.

Meropenem trihydrate (SM 7338 trihydrate) is a carbapenem antibiotic with broad-spectrum antibacterial activity.

Meropenem (SM 7338) sodium is a broad-spectrum carbapenem antibiotic that exhibits activity against both susceptible and resistant strains of Neisseria gonorrhoeae (MIC values of 0.02-0.06 mg mL), Haemophilus influenzae (MIC values of 0.03-0.12 mg mL), and Moraxella catarrhalis (MIC values of 0.015-0.12 mg mL).

Protected meropenem is a useful organic compound for research related to life sciences. The catalog number is T66294 and the CAS number is 96036-02-1.

Meropenem-d6 is a deuterated compound of Meropenem.

Meropenem-d6-1 is a deuterated compound of Meropenem-1. Meropenem-1 has a CAS number of 96036-03-2. Meropenem is a carbapenem antibiotic with broad spectrum of activity that is administered intravenously and used for severe bacterial infections due to sensitive agents. Meropenem is a common cause of mild transient aminotransferase elevations and can rarely result in clinically apparent, cholestatic liver injury.

Vaborbactam (RPX7009) is a β-lactamase inhibitor that is often used in conjunction with meropenem to study pneumonia and CRE infections.

NDM-1 inhibitor-8 (Compound 18b) is a covalent inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1), with an IC50 of 7.03 μM. It effectively inhibits resistant bacterial strains and demonstrates synergistic antibacterial effects when used in combination with Meropenem. In mouse models, NDM-1 inhibitor-8 exhibits anti-infective activity.

NDM-1 inhibitor-7 (Compound A8) is an NDM-1 inhibitor with an IC50 of 10.284 μM. It restores the ability of meropenem (MEM) to penetrate the cell wall of Gram-negative bacteria and effectively reinstates MEM's antibacterial activity against NDM-1 positive Escherichia coli. Moreover, NDM-1 inhibitor-7 demonstrates significant efficacy in both Galleria mellonella and murine peritonitis infection models.

Carbavance, a mixture of Meropenham and Vaborbactam, is intended for adults with complex urinary tract infections (cUTI), including pyelonephritis, a kidney infection caused by certain bacteria.

Metallo-β-lactamase-IN-6 is a highly effective inhibitor of VIM-Type metallo-β-lactamase, demonstrating IC50 values of 0.56 μM, 29.50 μM, and 5.78 μM for VIM-2, VIM-1, and VIM-5, respectively. Additionally, Metallo-β-lactamase-IN-6 exhibits potent synergistic antibacterial properties when combined with Meropenem, particularly against engineered Escherichia coli strains and clinically isolated Pseudomonas aeruginosa carrying the VIM-2 MBL gene [1].

Metallo-β-lactamase-IN-7 is a potent inhibitor of VIM-type metallo-β-lactamase with IC50 values of 0.019 μM, 13.64 μM, and 0.38 μM for VIM-2, VIM-1, and VIM-5, respectively. Metallo-β-lactamase-IN-7 also enhances the antibacterial activity of Meropenem against Gram-negative bacterial strains [1].

SA09-Cu is a potent, noncompetitive inhibitor of NDM-1, with an IC50 of 9.6 nM. It inactivates NDM-1 by oxidizing the enzyme's Zn(II)-thiolate site and resists reduction by bacterial intracellular thiols. SA09-Cu effectively restores Meropenem efficacy against various clinical NDM-1-producing carbapenem-resistant Enterobacteriaceae (CRE) and hampers the progression of carbapenem resistance [1].

K11, an antimicrobial peptide, demonstrates activity against MDR XDR K. pneumoniae isolates (MIC: 8-512 μg mL) and inhibits bacterial biofilm formation. It also acts synergistically with various antibiotics (Chloramphenicol, Meropenem, Rifampicin, etc.) to combat drug-resistant K. pneumoniae and exhibits high thermal and wide pH stability [1].

MBL-IN-3 (compound 72922413), a potent inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1) with an IC50 value of 54±4 μM, effectively reduces the minimum inhibitory concentrations (MICs) of Meropenem against clinical isolates of E. coli and K. pneumoniae that express NDM-1. This compound is utilized in studies focused on antibiotic sensitizer research [1].

NDM-1 Inhibitor-5 (compound 57) exhibits strong inhibition of NDM-1, characterized by a K i of 2.5 μM. Additionally, it demonstrates synergistic antibacterial effects when combined with meropenem [1].

Anti-MRSA agent 16 (Compound 4) acts as an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA). When used in combination with oxacillin or meropenem, it proves effective in treating infected mice.